Celltrion Celebrates Brazilian Tender Win For Infliximab
Remsima Win Follows Truxima (Rituximab) And Herzuma (Trastuzumab) Biosimilars
Executive Summary
Celltrion’s Remsima infliximab biosimilar has won a Brazilian federal tender as well as several individual state bids, following earlier awards for the Korean firm’s Truxima (rituximab) and Herzuma (trastuzumab) biosimilars.